Tipranavir: a new protease inhibitor for the pediatric population.
Highly active antiretroviral therapy can provide sustained viral suppression and a beneficial immunological response in both antiretroviral-naive and -experienced pediatric patients infected with HIV. While there have been many antiretroviral studies in adults infected with HIV, considerably less information is available in similar HIV-infected pediatric or adolescent patients. Tipranavir, a new-generation protease inhibitor approved for use in adults with resistant HIV strains, has recently been studied in HIV-infected children and adolescents. In this article, we summarize available pharmacokinetic, safety, tolerability and efficacy data obtained from children and adolescents treated with a pediatric tipranavir formulation.
Courter
Joshua D
JD
University of Connecticut School of Pharmacy, Department of Pharmacy Practice, Storrs, CT, USA.
Girotto
Jennifer E
JE
Salazar
Juan C
JC
D000293:Adolescent; D019380:Anti-HIV Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D011725:Pyridines / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D011753:Pyrones / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D013449:Sulfonamides
D019380:Anti-HIV Agents; D011725:Pyridines; D011753:Pyrones; D013449:Sulfonamides; C107201:tipranavir